Type 2 Diabetes Mellitus Completed Phase 3 Trials for Linagliptin (DB08882)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02015299Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early DiabetesTreatment
NCT02752113Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 DiabetesTreatment
NCT02851745Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular GeometryTreatment
NCT01243424CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesTreatment
NCT02453555Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes MellitusTreatment
NCT02897349Linagliptin Add-on to Insulin Background TherapyTreatment
NCT01084005Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 DiabetesTreatment
NCT00798161Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial DesignTreatment
NCT00602472BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 DiabetesTreatment
NCT00740051A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is InappropriateTreatment
NCT01204294Comprehensive Add on Study in JapanTreatment
NCT01087502Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal ImpairmentTreatment
NCT00622284Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesTreatment
NCT01422876Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsTreatment
NCT0118301330 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksTreatment
NCT00601250Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 DiabetesTreatment
NCT00819091Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea DrugTreatment
NCT00800683Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background InclusiveTreatment
NCT01194830Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-studyTreatment
NCT00621140Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic ControlTreatment
NCT00915772Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg BidTreatment
NCT00954447Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 DiabetesTreatment
NCT01734785Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesTreatment
NCT01708902Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 PatientsTreatment
NCT00654381Japanese P III vs Voglibose and PlaceboTreatment
NCT00641043Efficacy vs Placebo as Initial Combination Therapy With PioglitazoneTreatment
NCT00736099Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DMTreatment
NCT01215097Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin TherapyTreatment
NCT01792518MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptinTreatment
NCT00996658Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With PioglitazoneTreatment
NCT01214239Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic ControlTreatment
NCT01835678Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.Treatment